Biotech News

Adial Pharmaceuticals Expands Intellectual Property Portfolio with New U.S. Patent Granted for Genetic-Based Treatment of Alcohol and Opioid Use Disorders

Adial Pharmaceuticals (ADIL)Adial Pharmaceuticals2025-05-01 08:30 ESTCompany update

New patent covers a treatment method for a broad spectrum of alcohol-related disorders, including additional conditions associated with alcohol use

GLEN ALLEN, Va., May 01, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) ("Adial" or the "Company"), a clinical-stage...

Adial Pharmaceuticals

Adial Pharmaceuticals is a clinical-stage biotechnology company focused on treatments for alcohol use disorder and related addiction biology. Its story is centered on the difficult intersection of behavioral health, relapse prevention, and chronic disease management.

Recent company news

ADILAdial Pharmaceuticals2025-06-11 08:00 EST

Stock data

Close: 6.22 USD
Market cap: 5.06M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States

Adial Pharmaceuticals Expands Intellectual Property Portfolio with New U.S. Patent Granted for Genetic-Based Treatment of Alcohol and Opioid Use Disorders

Related news

Adial Pharmaceuticals Granted New U.S. Patent Expanding Coverage of its Genetic-Based Approach to Treating and Diagnosing Alcohol Use Disorder and Other Drug Dependencies

Adial Pharmaceuticals Granted Key U.S. Patent for the Treatment of Alcohol and Drug Dependence Based on Expanded Genotype Combinations

Adial Pharmaceuticals

Recent company news

Adial Pharmaceuticals Advances Toward Phase 3 Development for AD04

Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

Adial Pharmaceuticals Receives Milestone Payment from Adovate Following Initiation of Phase 1 Study

Adial Pharmaceuticals Granted End of Phase 2 Meeting from the U.S. Food and Drug Administration

Adial Pharmaceuticals Announces a Warrant Inducement Transaction for $2.75 Million in Gross Proceeds

Stock data